Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OIO vs BGLC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BGLC Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 6–2 Matrix Metrics)

BGLC Overall Winner 6-Pillar Tally: OIO 0 – 3 BGLC (3 Tie) Matrix Metrics: OIO 2 – 6 BGLC

As of Nov 16, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over OIO (OIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OIO carries a Unified Composite Score of 36.4/100 (SELL) at $1.70 (N/M Forward P/E, N/A operating margin), whereas BGLC carries 47.9/100 (HOLD) at $0.82 (N/M Forward P/E, -88.2% operating margin).

  • Technical & Structure Timing Caution: OIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.3); meanwhile BGLC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OIO vs BGLC
OIO US Equity
OIO
Institutional Equity
$1.70
+1.19% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.12β · 53% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 22.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.2%), weak momentum, RSI 44
RSI-14: 44.3 · SMA20: $1.81 · SMA50: $1.79
BGLC NASDAQ Head-to-Head Winner
BioNexus Gene Lab Corp Common stock
Services-Medical Laboratories
$0.82
-0.12% 1D
Market Cap $2.4M
TTM Revenue $3.1M
Forward P/E N/M
Beta / 30D Vol 1.33β · 84% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 53.0 Fund 56.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 34
RSI-14: 33.5 · SMA20: $0.99 · SMA50: $1.21

6-Pillar Scorecard Institutional Category Breakdown (OIO 0 – 3 BGLC)

Columns: Metric · OIO · BGLC
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BGLC
Revenue Growth (YoY) N/A -96.6%
Earnings Growth (YoY) N/A -95.0%
TTM Revenue (USD) N/A $3.1M
Market Cap N/A $2.4M
3. Profitability & Quality BGLC
Gross Margin N/A 12.3%
Operating Margin N/A -88.2%
Net Profit Margin N/A -82.4%
Return on Equity (ROE) N/A -33.7%
4. Balance Sheet & Cash Flow BGLC
Cash Generation (TTM) N/A -$1.2M
Cash Flow Margin N/A -38.1%
Net Cash / Leverage N/A ROE $3.7M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Specialty Chemicals Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OIO (2) vs BGLC (6)
Institutional Metric OIO BGLC Criterion Row Edge
Market Capitalization
Scale
N/A $2.4M Larger Scale BGLC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -96.6% Higher Growth BGLC
Operating Margin (TTM)
Profitability
N/A -88.2% Higher Margin BGLC
Net Profit Margin
Profitability
N/A -82.4% Higher Margin BGLC
Return on Equity (ROE)
Capital Efficiency
N/A -33.7% Higher ROE BGLC
52-Week Range Position
Momentum
6% ($1–$8) 0% ($1–$5) Stronger Trend OIO
Beta / 30D Volatility
Risk Regime
-0.12β · 53% Vol 1.33β · 84% Vol Lower Realized Risk OIO
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 47.9 / 100 (HOLD) Higher Composite BGLC
Trailing 12M Revenue (USD)
Operating Scale
N/A $3.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 12.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$1.2M ($3.7M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OIO +27.24 pp
OIO: -4.49% · BGLC: -31.73%
3M Horizon OIO +34.95 pp
OIO: -12.82% · BGLC: -47.77%
6M Horizon OIO +54.1 pp
OIO: -4.49% · BGLC: -58.59%
1Y Horizon OIO +6.55 pp
OIO: -55.84% · BGLC: -62.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OIO vs BGLC. Trailing 12-month operating profitability (OIO N/A vs BGLC -88.2%) and valuation multiples (OIO N/M vs BGLC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BGLC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.1M
Gross Margin12.3%
Op. Margin-88.2%
ROE / Fwd P/E-33.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BGLC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGLC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OIO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BGLC Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $2.4M market capitalization and -88.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OIO vs BGLC Key Questions & Quantitative Answers

As of Nov 16, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over OIO (OIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OIO carries a Unified Composite Score of 36.4/100 (SELL) at $1.70 (N/M Forward P/E, N/A operating margin), whereas BGLC carries 47.9/100 (HOLD) at $0.82 (N/M Forward P/E, -88.2% operating margin). Technical & Structure Timing Caution: OIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.3); meanwhile BGLC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BGLC leads the Growth & Scale pillar: OIO posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BGLC at -96.6% YoY revenue growth and -95.0% YoY earnings growth on $3.1M TTM revenue (12.3% gross margin, -88.2% operating margin). On trailing 12-month operating scale, OIO generates N/A in USD-normalized revenue versus $3.1M for BGLC. In operating R&D and SG&A reinvestment, OIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BGLC.

OIO and BGLC trade at balanced relative valuation multiples. OIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BGLC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-38.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OIO (N/A ROE) versus BGLC (-33.7% ROE) capital efficiency.

In options market volatility and institutional positioning, OIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.12β · 53% Vol realized risk). By comparison, BGLC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.33β · 84% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.